Bicyclic Bis-Heteroaryl Modulators for Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, and cancer lack effective inhibitors of protein aggregation, particularly targeting early aggregation processes and cell-to-cell propagation of toxic protein aggregates.
Innovation Solution
Development of bis-heteroaryl derivatives, specifically compounds of Formula (I), which modulate, prevent, or inhibit protein aggregation by interacting with misfolded proteins, thereby blocking their oligomerization and propagation, and are used in pharmaceutical compositions for treating neurodegenerative diseases and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then existing therapeutic options are available, but effective inhibition of protein aggregation is lacking
Solution Approach 1:
The patent segments the protein aggregation process into distinct stages (misfolding, oligomerization, fibril formation) and develops compounds that specifically target the early oligomerization stage. The bis-heteroaryl derivatives are designed to bind to and inhibit toxic oligomers, preventing their formation and propagation without interfering with normal protein function.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that bind between misfolded proteins to prevent their aggregation. These compounds act as molecular chaperones or blockers, interfering with the interaction between toxic oligomers and preventing their propagation to adjacent cells.
2Reliability
If compounds targeting early aggregation processes are developed, then specific inhibition of toxic oligomers is achieved, but pharmaceutical properties and drug-like characteristics are limited
Solution Approach 1:
The patent systematically varies structural parameters of the bis-heteroaryl compounds, including substituent types, ring sizes, and molecular weight, to optimize both binding affinity for toxic oligomers and pharmaceutical properties. This structure-activity relationship (SAR) optimization ensures the compounds meet drug-like criteria while maintaining specific inhibition of protein aggregation.
3Duration of action of moving object
If protein aggregation is inhibited, then disease progression is slowed, but the complexity of targeting multiple aggregation pathways increases
Solution Approach 1:
The patent develops bis-heteroaryl derivatives with universal binding capability that can inhibit aggregation of different neurodegenerative disease proteins (α-synuclein, tau, amyloid-beta) through a common mechanism. This multi-functional approach allows a single compound class to address multiple disease pathways without requiring separate targeted therapies for each protein.
Data Source
AI summary
The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.